This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Lilit Kazangyan
Lilit Kazangyan
Associate
New York +1 212 841 1115 lkazangyan@cov.com Download V-card

Lilit Kazangyan practices corporate and securities law, with an emphasis on domestic and international capital markets transactions. She also advises on general corporate matters, including securities laws compliance and corporate governance. Her clients include global investment banks acting as underwriters and placement agents as well as public and private companies.

  • Represented the underwriters in the initial public offering and subsequent follow-on offering of NeuroDerm Ltd., an Israel-based clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders.
  • Represented the underwriters in the initial public offering and subsequent follow-on offering of Affimed N.V., a German-based clinical-stage biotechnology company focused on cancer immunotherapies.
  • Represented the underwriters in the initial public offering and subsequent follow-on offering of uniQure N.V., a Netherlands-based biotechnology company focused on gene therapies.
  • Represented the underwriters in several public offerings of debt and equity for Senior Housing Properties Trust, a real estate investment trust that invests in senior living properties.
  • Represented the underwriter in the initial public offering of Presbia PLC, an Ireland-based ophthalmic device company marketing an optical lens implant for treating presbyopia.
  • Represented the underwriters in the initial public offering of OncoMed Pharmaceuticals, Inc., a U.S.-based clinical-stage biopharmaceutical company developing antibody therapeutics targeting cancer stem cells.
  • Represented the underwriters in several follow-on equity offerings for Celldex Therapeutics, Inc., a biopharmaceutical company focused on cancer immunotherapies.
  • Represented the underwriters in several follow-on equity offerings for Exact Sciences Corporation, a molecular diagnostics company focused on early detection of colorectal cancer.